ABSTRACT The production rates (PR) and the metabolic clearance rates (MCR) of human folliclestimulating hormone (HFSH) were determined in six pre-and five postmenopausal women. Human FSH (PER-780) labeled with 'I to specific activities of 50-150 /Ac/,ug was used as a tracer. Both double antibody and trichloroacetic acid (TCA) precipitation techniques were used to determine HFSH-'I levels in infusate and plasma. In four of the subjects MCRs measured by both constant infusion and single injection techniques were the same. By constant infusion, plasma HFSH-2'I levels reached equilibrium between 4-5 hr.
INTRODUCTION
Circulating plasma levels of human follicle-stimulating hormone (HFSH) measured at any single point in time are the resultant of both the rate at which the hormone is secreted into the blood by the pituitary and the rate at which the hormone is degraded or cleared from the blood by target glands or other organs. Changes in plasma HFSH levels may reflect changes in rates of either or both of these processes. Conclusions concerning the relative contributions of entry and exit of the hormone from the blood depend upon measurements of metabolic clearance rates (MCR) in steady states associated with different plasma hormone concentrations.
The purpose of the present study was to determine the MCRs of HFSH in premenopausal and postmenopausal women by the constant infusion of tracer hormone and to estimate the production rates (PR) from these MCRs and the endogenous HFSH levels determined by radioimmunoassay.-We have also compared the single injection and constant infusion techniques for estimating MCRs in several patients. Simultaneus MCRs of HFSH and human luteinizing hormone (HLH) were measured in a single patient by both methods.
METHODS
Subjects. Studies were performed on seven premenopausal and six postmenopausal women (Table I) . Six premenopausal subjects were normal volunteers studied at random times during their menstrual cycles. The seventh premenopausal subject had infertility associated with amenorrhea and galactorrhea (No. 7). Four of the postmenopausal women had carcinoma of the breast with metastases (Nos. 9, and 11-13). One of these four had had a hypophysectomy (No. 13). None had evidence of metastases to the liver or abnormal liver fucntion tests. All subjects were active but were at bed rest and received clear liquid diets during infusions. Saturated potassium iodide, six drops every 6 hr, was administered for 24 hr preceding and 24 hr after initiation of the study in order to block thyroid trapping of radioactive iodine.
Endogenous hormone measurement. Plasma HFSH and HLH levels were determined by double antibody radioimmunoassays expressed as milliinternational units of International Reference Preparation No. 2 human menopausal gonadotropin (mU of IRP No. 2 HMG) (footnotes 1 and 2 and references 1 and 2) which was used as standard in both assays. In the HFSH assay, preparation R-780' was labeled as trace hormone. A minimal detectable quantity was 1 mU or less. Within assay precision had 95% confidence limits of ±1.6-1.9 mU/ml for values in the range seen in young normal adult women. Studies for specificity revealed less than 1% cross-reactivity for HLH, human growth hormone (HGH), human chorionic gonadottophin (HCG), and adrenocorticotrophic hormone (ACTH) when compared to HFSH on a weight basis.' Thyroid-stimulating hormone (TSH) cross-reactivity was 3.5% at the doses tested.
Preparation of tracer hormone. 
RESULTS
Endogenous HFSH levels for the premenopausal women were 10 +1.8 mU/ml (mean ± SE) ( Table I ). The two lowest values, found in subject Nos. 4 and 6, were obtained during the late luteal phase of the menstrual cycles. Plasma HFSH levels for the postmenopausal women were 172 ±24 mU/ml. The low HFSH plasma concentration in patient No. 13 was the result of hypophysectomy. Endogenous plasma HFSH determinations at intervals throughout several of the studies showed no effect of either injection or constant infusion of tracer HFSH on endogenous levels.
During constant infusion studies, plasma HFSH-mlI and HFSH-l'I appeared to reach equilibrium within 4-5 hr (Fig. 1) Table I .
During simultaneous infusion of HFSH-'I and HLHY-I, HLH appeared to attain equilibrium within 3 hr, approximately 2 hr faster than HFSH (Fig. 1) . The MCR for HLH was 18.5 ml/min and for HFSH was 10.8 ml/min determined with both tracers at equilibrium in this subject.
Disappearance of tracer from plasma after intravenous injection was observed in four subjects previously studied by constant infusion. The difference in clearance of tracer HLH and HFSH from plasma is demonstrated by their disappearance curves after simultaneous injection (Fig. 2) . The disappearance curves on semilogarithmic plot had no clearly linear segment, an observation suggesting a multicompartmental system.
The MCRs determined by the single injection technique and the constant infusion method were approximately the same (Table II) Within 24 hr 57.3% of 'I was excreted in the urine. By 48 hr 75% was excreted. 8-29% of 'I injected was excreted in the urine in a form precipitable by TCA in 24 hr.
DISCUSSION
Two major assumptions are necessary for MCR measurements to be valid. First the tracer used is assumed to be cleared from the plasma in a manner identical with that of the endogenous hormone. Secondly, secretion and clearance should be in a steady state during the course of the study. Evidence in support of the first assumption was obtained from studies on subhuman primates. Although we did not have a sufficient quantity of purified HFSH to perform clearance studies of unlabeled hormone in humans, iodinated and unlabeled HFSH had indistinguishable disappearance curves when injected simultaneously into six female Macaca mulatta monkeys.' The second assumption. that a steady state existed during the studies, appears justified since endogenous plasma HFSH levels did not vary during three studies. In addition, a steady state must have been reached in regard to clearance because constant plasma HFSH-2'I levels were attained during the infusion (6, 7 Tr ME-HOURS FIGURE 2 Typical disappearance curves of u5I-labeled HFSH and of 13'I-labeled HLH after a single intravenous injection. The labeled hormones were simultaneously administered to this subject and were precipitated from plasma by the double antibody method.
The multiexponential disappearance curves of HFSH-3'I from plasma after a single injection are similar to those previously noted for HLH (7) and suggest that both hormones are distributed in more than one compartment. This suggestion is supported by the nearly (9) . Gay and Bogdanove have also found that in rats the disappearance of endogenous LH from plasma was considerably faster than the disappearance of FSH (10) .
The mean per cent of radioactivity injected as HFSH-'I and recovered in the urine was 57% within 24 hr and 75%, within 48 hr. 8-29% of the injected HFSH-'I was found in a TCA-precipitable form in urine excreted during the first 24 hr after infusion (mean, 17%), whereas 3-22% was precipitated from aliquots of the same urine (mean, 12%,D) by a double antibody method. This discrepancy in the two precipitation methods appeared only in urine and not in plasma. It is possible that TCA precipitates some partially degraded hormone not recognized by the specific antibody. Alternately, some factor in urine may interfere with the antigen-antibody reaction.
Becker and Albert found that urinary excretion of biologically active HFSH in premenopausal women ranged from 0.18 to 0.36 mg of NIH-FSH-S1/24 hr. whereas in postmenopausal women it was 3.7 mg/24 hr (11) . Converted into units of IRP No. 2 HMG (1 mg of NIH-FSH-S1 = 25 U) (12) , urinary excretion would be 4.5-9 U/24 hr for premenopausal women and 92.5 U/24 hr for postmenopausal women. Based on our results, PRs of HFSH are 210 U/24 hr in premenopausal women and 3038 U/24 hr in postmenopausal women. On this basis 24 hr urinary excretion of biologically active gonadotropin represents only 3-5% of the quantity produced in 24 hr. The 11-fold increase in urinary excretion of HFSH at menopause reported by Becker is similar to the 15-fold increase in production at menopause found in this study.
Keller found the renal clearance of HFSH by bioassay to be 0.16-0.7 ml/min (mean 0.58) (13) . On the basis of a mean MCR of 13.4 ml/min, urinary excretion would account for less than 5% of the MCR.
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